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Objective. To evaluate, in three Spanish tertiary referral centres, the short-term safety and efficacy of golimumab (GLM) for
treatment of immune-mediated uveitis resistant to previous immunosuppressive therapy.Methods. Nonrandomized retrospective
interventional case series. Thirteen patients with different types of uveitis that were resistant to treatment with at least 2 previous
immunosuppressors were included in this study. All included patients were treated with GLM (50mg every four weeks) during at
least 6months. Clinical evaluation and treatment-related side effectswere assessed at least four times in all included patients.Results.
Eight men and 5 women (22 affected eyes) with a median age of 30 years (range 20–38) and active immune-mediated uveitides
were studied. GLM was used in combination with conventional immunosuppressors in 7 patients (53.8%). GLM therapy achieved
complete control of inflammation in 12/13 patients (92.3%) after six months of treatment. There was a statistically significant
improvement in mean BCVA (0.60 versus 0.68, 𝑃 = 0.009) and mean 1mm central retinal thickness (317 versus 261.2 𝜇, 𝑃 = 0.05)
at the six-month endpoint when compared to basal values. No major systemic adverse effects associated with GLM therapy were
observed. Conclusions. GLM is a new and promising therapeutic option for patients with severe and refractory uveitis.
1. Introduction
Corticosteroids remain the mainstay of treatment for the vast
majority of patients with immune-mediated uveitis [1]. How-
ever, those patients with active inflammation who are intoler-
ant of or unresponsive to steroids require therapy with other
immunosuppressive agents trying to prevent the potential
sequelae associated with this vision-threatening condition.
The off-label use of biologic agents and particularly those
blocking tumor necrosis factor-alpha (TNF-𝛼) has demon-
strated encouraging results when employed for management
of patients with immune-mediated uveitis refractory to con-
ventional treatment since their first reported use in 2001 [2].
Potential advantages of these agents when compared with
traditional immunosuppressors include a substantial efficacy
in recalcitrant cases [3], as well as a lower total immunosup-
pressive load [4], a rapid clinical effect [5], good safety profile
[6], and significant improvement in quality of life [7].
The present evidence shows that infliximab and adal-
imumab have the highest level of evidence and grade of
recommendation, and thus both may be considered as first-
line or second-line immunomodulatory agents for treatment
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Table 1: Demographic and diagnostic information of all included patients.
Patient number Age Sex Affected eye Associated disease Location of uveitis AC infl (SUN) Vitr infl (SUN) Macular edema1
1 36 M OD Psoriatic arthritis Anterior Active Inactive No
2 20 F OU Sarcoidosis Panuveitis Active Inactive Yes
3 27 M OU Sarcoidosis Intermediate Inactive Active No
4 31 F OD Psoriatic arthritis Anterior Active Inactive No
5 34 M OD JIA Anterior Active Inactive No
6 37 M OS Axial SpA Anterior Active Active Yes
7 22 M OU VKH Panuveitis Active Active Yes
8 32 M OU Axial SpA Anterior Active Inactive Yes
9 21 F OU JIA Anterior Active Inactive Yes
10 23 F OU JIA Anterior Active Inactive Yes
11 24 F OU JIA Anterior Active Inactive No
12 38 M OU Behc¸et Panuveitis Active Active Yes
13 30 M OU Behc¸et Panuveitis Inactive Active Yes
M:male; F: female; OD: right eye; OS: left eye; OU: both eyes; JIA: Juvenile idiopathic arthritis; VKH: Vogt-Koyanagi-Harada syndrome; Ac infl (SUN): anterior
chamber inflammation base on Standardization of uveitis nomenclature criteria. (Ref.) Vitr infl (SUN): vitreous inflammation base on Standardization of uveitis
nomenclature criteria. (Ref.).
1Macular edema was defined as central macular thickness >300𝜇 and/or presence of intraretinal cysts in optical coherence tomography (Cirrus HD-OCT, Carl
Zeiss Meditec, Dublin, CA, USA). The 1 mm central retinal thickness was evaluated using the macular cube strategy 512 × 128.
of immune-mediated uveitis depending on which systemic
immunologic disorder is associated with the intraocular
inflammation [6, 8].
Golimumab (GLM) (trade name Simponi), a fully human
anti-TNF-𝛼 monoclonal antibody, was approved by the
US Food and Drug Administration in 2009 for the use
with methotrexate (MTX) in adults with moderate-to-severe
active rheumatoid arthritis (RA) and with or without MTX
or other biologic disease-modifying antirheumatic drugs in
adults with active psoriatic arthritis (PsA) or active ankylos-
ing spondylitis (AS) [9]. We report the first use of GLM for
treatment of noninfectious uveitis in 2011 [10]. Some other
studies have addressed the potential use ofGLMfor treatment
of uveitis, mainly associated with rheumatologic conditions
[11, 12].Wewould like to present the results from threeUveitis
Units in Spainwhen usingGLM for treatment of patientswith
immune-mediated uveitis of various etiologies that had been
resistant to several immunosuppressive agents.
2. Materials and Methods
Nonrandomized Retrospective Interventional Case Series.
Patients with different types of active immune-mediated
uveitis that had been resistant to local and systemic corti-
costeroids and at least one additional immunosuppressive
agent and who were treated with GLM during at least 6
months were included in this study. All included patients
had an associated systemic immune-mediated disease. Table 1
lists demographic and diagnostic information for the 13
patients who form the basis of this report. In 12/13 patients
(92.3%) GLM was at least the second biologic agent used
for treatment of uveitis, whereas GLM was used as first-line
biologic therapy in one patient (patient 6). Table 2 shows
previous treatment regimens employed for management of
uveitis in all included patients. Table 3 shows the reasons
for discontinuation of previous biologic therapy. We defined
Table 2: Previous immunosuppressive therapies in all included
patients.
Previous treatment
CsA 2
AZA 1
MTX 11
Bolus of methylprednisolone i.v. 2
Biologic therapy
First biologic drug used:
IFX 8
ADA 3
ETN 1
Monotherapy/combined treatment 4/9
Second biologic drug used
ADA 6
ETN 1
Monotherapy/combined treatment 1/6
Third biologic drug used
Certolizumab 1
Abatacept 2
Monotherapy/combined treatment 0/3
Fourth biologic drug used
ETN 1
Monotherapy/combined treatment 0/1
CsA: cyclosporine A; AZA: azathioprine; MTX: methotrexate; IFX: inflix-
imab; ADA: adalimumab; ETN: etanercept.
primary failure as an absence of a two-step decrease in level
of inflammation (e.g., anterior chamber and/or vitreous cells)
or a decrease to grade 0. Secondary failure was defined as
inflammatory relapse after previous control of inflammation.
We classified “control of inflammation” as grade 0 cells in
both anterior and posterior segments in addition to absence
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Table 3: Reasons for discontinuation of previous biologic therapy.
First biologic drug used
Primary failure 5
Secondary failure 2
Toxicity 3
Second biologic drug used
Primary failure 3
Secondary failure 4
Toxicity 0
Third biologic drug used
Primary failure 2
Secondary failure 1
Toxicity 0
Fourth biologic drug used
Primary failure 1
Secondary failure 0
Toxicity 0
of other signs of intraocular inflammation (cystoid macular
edema (CME) and vasculitis).
All included patients received 50mg of subcutaneous
GLMevery fourweeks during at least 6monthswithoutmod-
ifications during the follow-up. Chest X-ray, tuberculin skin
test, andQuantiferon-TBGold were performed in all patients
before treatment. GLM was the only immunomodulatory
agent used in six of them. In seven patients, GLM was used
alongside previous immunosuppressors, without any dosage
modification throughout the study. Topical steroids were
used by three patients (patients 6, 8, and 9) at the beginning
of the follow-up and were slowly tapered and discontinued
after one month in all of them.
Uveitis clinical evaluation was performed at least four
times (before treatment and 1, 3, and 6months after initiation
of therapy with GLM) in all included patients. Clinical
evaluation included visual acuity (BCVA; best-corrected
Snellen VA) and ophthalmic examination. Anterior chamber
was graded according to the classification established by
the standardisation of uveitis nomenclature; whereas the
national eye institute systemwas adopted for grading vitreous
inflammation [13, 14]. Optical coherence tomography (Cirrus
HD-OCT, Carl Zeiss Meditec, Dublin, CA, USA) was used
before and after treatment in both groups of patients to
determine the presence of CME. The 1mm central retinal
thickness was evaluated using the macular cube strategy 512
× 128 in all patients at each study visit. Macular edema was
defined as central macular thickness >300 𝜇 and/or presence
of intraretinal cysts in OCT. Fluorescein angiogram (FA)
was performed routinely before and after starting treatment
(between 1 and 3 months after initiation of therapy) to
determine the presence or absence of retinal angiographic
leakage. FA was reviewed for presence or absence of retinal
vasculitis and/or CME.
Treatment-related side effects were assessed on each visit
with a thorough review of systems and complete blood-cell
counts, blood urea nitrogen (BUN) level, creatinine level, and
liver function test parameters obtained on an every study visit
basis.
Statistical analysis was performed using the software
STATISTICA (StatSoft Inc. Tulsa, Oklahoma, USA). Results
were expressed as mean ± SD for variables with a normal dis-
tribution or as median (25th–75th interquartile range (IQR))
when they were not normally distributed. The comparison of
continuous variables was performed using theWilcoxon test.
3. Results
Eight men and 5 women (22 affected eyes) with a median
age of 30 years (range 20–38) and active immune-mediated
uveitides were studied. Uveitis was anterior in 8 patients
(61.5%), intermediate in 1 patient (7.6%), and panuveitis in
4 patients (30.7%). All included patients (13/13) received
previous treatment with systemic steroids (using intravenous
pulses of methyl-prednisolone) in two of them. In addi-
tion, four patients (30.7%) received coadjuvant intraoc-
ular steroids (2 intravitreal triamcinolone injections and
2 dexamethasone intravitreal implants). About traditional
immunosuppressors, all included patients had been treated
withmethotrexate at any time prior to GLM therapy, whereas
cyclosporine A was used in 2 (15.38%), azathioprine in 1
(7.6%), tacrolimus in 1 (7.6%), mycophenolate mofetil in 1
(7.6%), cyclophosphamide in 1 (7.6%), and leflunomide in 1
(7.6%). Only one patient received GLM as first-line biologic
therapy, whereas 12 patients received previous treatment with
at least one other biologic agent. From the latter, 12 patients
received treatment with at least one biologic drug prior to
GLM, 7 patients (53.8%) received treatment with at least 2
biologics, 3 patients (23%) received treatment with at least
3 biologics, and 1 patient (7.6%) received treatment with at
least 4 biologics. Infliximab (IFX) was used as first biologic
agent in 8 patients (61.5%), adalimumab (ADA) in 3 patients,
(23%), and etanercept (ETN) in 1 patient (7.6%). Mean time
on first biologic treatment was 14.7 months (range 1–50).
ADA was used as second biologic agent in 6 patients (46.1%)
and ETN in 1 patient (7.6%). Mean time on second biologic
agent was 25.5 months (range 15–57). Abatacept was used as
third biologic agent in 2 patients (15.3%) and certolizumab in
1 patient (7.6%). Mean time on third biologic agent was 11.6
months (range 2–18). ETN was used as fourth biologic agent
in 1 patient (7.6%) during 7 months.
Coadjuvant immunosuppressive therapy was used in 7
of the studied patients including methotrexate (4 patients),
azathioprine (1 patient), mycophenolate mofetil (1 patient),
and leflunomide (1 patient). Mean time from onset of uveitis
to GLM therapy was 97.4 months.
GLM therapy achieved complete control of inflammation
in 12/13 patients (92.3%) after six months of treatment. The
mean BCVA increased from a basal value (before initiation
of GLM) of 0.60 to 0.68 at the six-month endpoint (𝑃 =
0.009). Only one patient, patient number 12, showed a score
of anterior chamber and/or vitreous inflammation different
than zero at the six-month endpoint. The mean 1mm central
retinal thickness decreased froma basal value of 317 to 261,2 at
the six-month endpoint (𝑃 = 0.05). Figure 1 shows changes in
mean values of macular thickness (1mm central thickness) of
all included patients over the study period.There was no evi-
dence of active retinal vasculitis before initiation of therapy in
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Figure 1: Rapid and maintained improvement of macular thickness
(1mm central retinal thickness, macular cube strategy 512×128, and
Cirrus-HDOCT) following the onset ofGolimumab (data expressed
as mean values compared with basal results).
any of the included patients. Fluorescein angiogram results
did not differ from those observed with OCT regarding the
presence of CME.
No major systemic adverse effects were observed. Only
a mild and local cutaneous reaction was recorded in two
patients (patients 5 and 9) among all included patients over
the entire study period.
4. Discussion
These results suggest that GLM is well tolerated and is
associated with control of inflammation in 92,3% of a hetero-
geneous group of immune-mediated uveitis patients resistant
to traditional therapy and other biologic agents. The use
of GLM is also associated with short-term improvement in
mean values of BCVA and decrease of mean values of central
retinal thickness. Despite the evident limitations of this study,
including its retrospective design, lack of a control group,
short follow-up, and limited number of patients, the results
suggest that further evaluation of thismodality is appropriate.
TNF-𝛼 is recognized as one of the main inflammatory
cytokines involved in the pathogenesis of immune-mediated
uveitis [14–16]. This ubiquitous cytokine plays a key role in
initiating and maintaining the inflammatory processes by
orchestrating leukocyte infiltration, dendritic cell matura-
tion, and macrophage activation and driving T-helper lym-
phocytes’ response [17]. Therapy with two TNF-𝛼 inhibitors,
infliximab and adalimumab, has been proven to be effective
for treatment of immune-mediated uveitis with considerable
levels of recommendation and evidence [6, 8]. The clinical
efficacy of other TNF-𝛼 blockers such as GLM needs to
be demonstrated and thus this drug is considered only as
an alternative to those patients who have failed to respond
to first-line TNF-𝛼 inhibitors. However, it is necessary to
emphasize that not all patients respond to their first anti-TNF
agent, and so it is clearly useful to have a range of effective
therapeutic options to treat those patients with severe and
refractory immune-mediated uveitis. In this setting, the role
of GLM in the noninfectious uveitis treatment algorithm
needs to be further studied.
A potential limitation of these results could be related to
the inclusion of less severe uveitis considering that we include
8 patients with anterior uveitis. However, anterior uveitis in
these patientswas associatedwith juvenile idiopathic arthritis
(patients 5, 9, 10, and 11) and HLA-B27 + haplotype (patients
1, 4, 6, and 8). Despite recent therapeutic progress, JIA-
associated uveitis has a severe course and the potential for
long-term complications, including blindness [18]. HLA-B27
positive-associated anterior uveitis is associated with a sub-
stantially higher incidence of ocular complications and has
a much worse prognosis when compared with HLA-B27
negative-associated anterior uveitis [19]. Moreover, some of
the patients with anterior uveitis (patients 2, 9, and 11) had
concomitant macular edema, the most vision-threatening
complication associated with uveitis [20, 21]. In this setting,
we cannot consider all anterior uveitis as “benign” entities.
The seven cases that were included in our paper were severe
and vision-threatening cases refractive to conventional and
nonconventional treatment for such conditions.
Of note, patients included in the present study had a
severe inflammatory condition which was resistant to several
treatment-regimens inflammatory conditions. The positive
response observed in almost all included patients needs to
be analysed in this mentioned difficult clinical setting. This
inclusion bias in addition to the short follow-up may have
influenced the limited improvement in visual acuity observed
in our study considering the long and severe course of
intraocular inflammation in our patients.
Interestingly we observed a significant improvement in
central retinal thickness. TNF-𝛼 is one of the inflammatory
cytokines that upregulates intraocular production of VEGF
[22, 23], which plays a crucial role in the pathogenesis of
CME [24]. We have previously reported how another TNF-𝛼
blocker, adalimumab, induces a reduction in plasma VEGF
levels when employed for treatment of immune-mediated
uveitis, which may correlate with clinical improvement [25].
In our study GLM also demonstrated a beneficial effect on
CME thus strengthening the idea of a comparable efficacy
with first-line TNF-𝛼 blockers.
Previous reports on the use of GLM for treatment of
uveitis have focused on those patients with uveitis sec-
ondary to Behc¸et disease, juvenile idiopathic arthritis, and/or
HLA-B27 + haplotype. To the best of our knowledge, this
is the first report of GLM employed in the treatment of
uveitis associated with sarcoidosis, Vogt-Koyanagi-Harada
disease, and/or psoriatic arthritis. The increasing potential
treatment indications for GLMmay be of high interest in the
therapeutical decision making of chronic uveitis patients.
The main aim of this study is to show these encouraging
results on the use of GLM for treatment of immune-mediated
uveitis. Although these results are preliminary, further studies
including a higher and more homogeneous group of patients
are warranted.
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